Le Lézard
Classified in: Health
Subjects: PET, FVT, MAT

Pet Releaf, #1 Pet CBD Brand, Shares Resources For a Calmer, Safer Fourth of July


DENVER, June 21, 2023 /PRNewswire/ -- Ahead of the Fourth of July, Pet Releaf is sharing expert tips, resources, and CBD products to help keep pets calm and safe during fireworks. While the holiday weekend is the highlight of summer for many families, it also comes with a not-so-fun statistic: thousands of pets will go missing across the U.S. between July 4-6 this year.

Formulated by veterinarians and designed specifically for calming, Pet Releaf's Stress Releaf is perfect for July 4th.

"Loud noises can be terrifying for pets, but luckily, we have been helping pets stay calm and safe during fireworks and travel for more than a decade and have the products and resources to help families have a safe holiday."

Pet Releaf's line of Stress Releaf CBD Oils and Family-Sized Edibites were released in the past year to help give pet parents more ways to reduce stress.

The new Stress Releaf Hemp Oils are available in four varieties ? 300 mg for Small dogs, 600 mg for Medium/Large dogs, 180mg Feline Releaf Oil, and 1500mg Equine Releaf Oil. Formulated by veterinarians and designed specifically for calming and managing situational stress, the USDA Organic product contains Full Spectrum Hemp Oil and Ashwagandha.

Uses for pet CBD this July Fourth include:

Pet Releaf products are USDA Organic, NASC-certified, plant-powered, USA-made, veterinarian-developed, third-party tested, and made from high-quality ingredients. Although there are many pet CBD brands out there, Pet Releaf is the original and continues to innovate to provide the highest-quality products to 5 million pets and counting.

Pet owners preparing for fireworks season should order their CBD at petreleaf.com by June 27th or find a retailer near them.

For additional resources, deals, and top recommended calming products, check out Pet Releaf's free Pet Owner's Guide to July 4th.

To learn more about Pet Releaf, visit petreleaf.com. 

About Pet Releaf 

Pet Releaf is the original plant-based pet CBD brand ? supporting pets, their parents, and the planet with sustainably made, veterinarian-formulated hemp-based solutions. Since its founding more than a decade ago, the company has led the industry with its commitment to education, transparency, and most of all, effectiveness, and has transformed the lives of more than 5 million pets and their families. Sourced on regenerative farms in Colorado and awarded the NASC quality seal, Pet Releaf's products help reduce discomfort and irritation, support calm behavior and optimal digestion, and promote long-term health and general wellness. Learn more at petreleaf.com. 

Media Contact 
Miranda Carney 
[email protected]

SOURCE Pet Releaf


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: